Animi-3 is a prescription-only product with specially formulated and highly refined omega-3 fatty acids, phytosterols, prescription-strength folic acid, and vitamins B6 and B12. Although we make no claims regarding Animi-‘s efficacy in the treatment of disease, there are numerous studies that conclude that omega-3 supplementation offers significant benefits.
Which came first, the disease or the deficiency?
- Omega-3 (DHA & EPA)
- Folic Acid
- Vitamin B6 and B12
Addressing these deficiencies may reduce cardiovascular risk.*
Purity & Clinical Evidence
The omega-3 (DHA & EPA) in Animi-3 has been highly refined to remove contaminants commonly found in fish oils such as methylmercury and PCB’s. In fact, the omega-3 in Animi-3 is all natural, meets stringent purity regulations, and comes from a source that has earned U.S. Pharmacopeia (USP) verification, the body that establishes standards on fish oils for the FDA.
Animi-3 capsules are indicated for nutritional support and folic acid supplementation and provide assurance of dosing control for these vital nutrients.
Clinical evidence presented by leading researchers at Cornell University1 suggests that the combination of ingredients such as in Animi-3 can be a valuable addition to the physician’s therapeutic regimen.
Animi-3 Clinical Trial
PBM Pharmaceuticals, the maker of Animi-3, conducted a study for cardiovascular risk reduction and dementia by a leading heart disease specialist. The Animi-3 clinical study consisted of a six-month, double-blind, randomized, placebo-controlled trial in 75 subjects ages 55-80 years with no prior history of dementia.
The study started in September 2005 and was conducted by Ernst J. Schaefer, M.D., of Cardiovascular Research Associates, in Boston, MA. Dr. Schaefer is also a Professor of Medicine at Tufts University School of Medicine.
1 “Increased Consumption of Omega-3 Fatty Acids May Lower the Risk of Cardiovascular Disease, Dementia, and Inflammatory Disease” Conference, July 1, 2004. Supported by PBM educational grant.
* FDA “Qualified Health Claims” B vitamins & Vascular Disease. As part of a well-balanced diet that is low in saturated fat and cholesterol, Folic Acid, Vitamin B6 and Vitamin B12 may reduce the risk of vascular disease. FDA evaluated the above claim and found that, while it is known that diets low in saturated fat and cholesterol reduce the risk of heart disease and other vascular diseases, the evidence in support of the above claim is inconclusive. Docket No. 99P-3029.
FDA “Qualified Health Claims” Omega-3 Fatty Acids & Coronary Heart Disease. Consumption of omega-3 fatty acids may reduce the risk of coronary heart disease. FDA evaluated the above claim and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive. Docket No. 9IN-0103.